GLP-1 receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-12. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Venom evolved just once among all Toxicofera about 170 million years ago, and then diversified into the huge venom diversity seen today. The original toxicoferan venom was a very simple set of proteins that were assembled in a pair of glands. Subsequently, this set of proteins evolved independently in the various lineages of toxicoferans, including Serpentes, Anguimorpha, and Iguania. Several snake lineages have since lost the ability to produce venom, often due to a change in diet or a change in predatory tactics. In addition to this, venom strength and composition has changed due to changes in the prey of certain snake species. For example, the venom of the marbled sea snake (Aipysurus eydouxii) became significantly less toxic after the diet of this species changed from fish to strictly fish eggs. The evolution of venom is thought to be responsible for the enormous expansion of snakes across the globe. The mechanism of evolution in most cases has been gene duplication in tissues unrelated to the venom. Pre-existing salivary proteins are the likely ancestors of most venom toxin genes. Expression of the new protein in the venom gland followed duplication. Then proceeded natural selection for adaptive traits following the birth-and-death model, where duplication is followed by functional diversification, resulting in the creation of structurally related proteins that have slightly different functions.
Polyphenol oxidases are a family of di-copper metalloenzymes that include tyrosinase and catechol oxidase. In plants, both enzymes can catalyze the oxidation of ortho-diphenols substrates into their corresponding ortho-quinones. The key difference between the two related enzymes is that tyrosinase can catalyze the hydroxylation of monophenols to diphenols (monophenolase activity) as well as the oxidation of the o-diphenol to the o-quinone (diphenolase activity) whereas catechol oxidase only possesses diphenolase activity. When plant tissue is damaged, the chloroplast may rupture and release catechol oxidase into the plant cytoplasm, and vacuoles may also rupture, releasing stored catechol into the cytoplasm. The tissue damage also allows oxygen to penetrate into the cell. Thus, tissue damage facilitates the interaction of catechol oxidase with its substrate to produce o-benzoquinone, which can polymerize non-enzymatically to yield melanins that form an insoluble barrier for wound protection.
On March 20, 1976, Marrow's high school girlfriend Adrienne gave birth to their daughter LeTesha Marrow, and they continued attending high school while raising her. While filming Breakin' in 1984, he met his second girlfriend Darlene Ortiz, who was at the club where the film was shot. They began a relationship and Ortiz was featured on the covers of Rhyme Pays and Power. Ice-T and Ortiz had a son, Ice Tracy Marrow Jr., on November 23, 1991; Ice Marrow, aka "Little Ice", became a backing vocalist with Body Count in time for the recording of their album Carnivore. Ice-T married swimsuit model Coco Austin in January 2002. In celebration of their impending ninth wedding anniversary, the couple renewed their wedding vows on June 4, 2011. As of 2006, they owned a penthouse apartment in North Bergen, New Jersey. In 2012, they were building a five-bedroom house in Edgewater, New Jersey, that was expected to be completed by the end of the year. In 2015, the couple had their first child together, a daughter. Ice-T has stated on numerous occasions that he is a teetotaler, and lives a straight edge lifestyle. He is a long time practitioner of Brazilian Jiu-Jitsu and boxing, and is a big fan of the UFC.
=== Medium of instruction === At primary and secondary school levels, the government maintains a policy of "mother tongue instruction"; most schools use Cantonese as the medium of instruction, with written education in both Chinese and English. Other languages being used as the medium of instruction in non-international school education include English and Putonghua (Mandarin Chinese). Secondary schools emphasise "bi-literacy and tri-lingualism", which has encouraged the proliferation of spoken Mandarin language education. English is the official medium of instruction and assessment for most university programmes in Hong Kong, although Cantonese is predominant in informal discussions among local students and professors.
Sources: en.wikipedia.org
=== Mechanically powered submarines === Submarines could not be put into widespread or routine service use by navies until suitable engines were developed. The era from 1863 to 1904 marked a pivotal time in submarine development, and several important technologies appeared. A number of nations built and used submarines. Diesel electric propulsion became the dominant power system and equipment such as the periscope became standardized. Countries conducted many experiments on effective tactics and weapons for submarines, which led to their large impact in World War I.
One of those was the idea that when introducing a new mechanic, the level was designed to teach the new mechanic without potential harm to the player-character, followed by then testing that mechanic in a more harmful situation to the character. The team also included a brief mention to the long-fall boots from Aperture Science from the Portal series; Portal had come out after Half-Life 2 but loosely tied narratively to the Half-Life universe, and the team felt it appropriate to show the competing lab's technology within the Black Mesa facility from this connection. Once the team had gotten all but the Xen levels completed in the new Source engine they were content with, they released these on Steam's early access on May 5, 2015, to get feedback and bug testing, stating that the Xen sections were still a work in progress. This version also included the deathmatch multiplayer modes with some of Half-Life's remade maps. Early access also brought Crowbar Collective additional support from developers and artists to help with finalizing the project.
== Regulation == Prolactin cell regulation mainly involves dopamine, a prolactin production suppressor, estrogen, a prolactin production stimulator, and thyrotropin-releasing hormone (TRH), a prolactin release stimulator. Dopamine, the main inhibitor, keeps prolactin levels low. Dopamine is secreted by the hypothalamus during times of high prolactin levels, which in response lowers prolactin levels, a negative feedback mechanism. Estrogen, a stimulator, enhances the production of prolactin. During times of elevated estrogen levels, such as during pregnancy, prolactin production is increased. TRH stimulates the release of prolactin from the pituitary gland. TRH, also released by the hypothalamus, binds to receptors on prolactin cells, activating cellular signaling pathways that promote prolactin secretion.
Pyridine carboxylic acids: The pyridine carboxylic acids are more acidic than benzoic acid. They undergo reactions ordinarily associated with carboxylic acids, i.e. esterification, amide formation, acid chloride formation. Vinylpyridines: The dominant reaction of 2-vinylpyridine is its copolymerization with styrene and butadiene for the production of rubber tires.
Neurapraxia is the least severe form of nerve injury, with complete recovery. In this case, the axon remains intact, but there is myelin damage causing an interruption in conduction of the impulse down the nerve fiber. Most commonly, this involves compression of the nerve or disruption to the blood supply (ischemia). There is a temporary loss of function which is reversible within hours to months of the injury (the average is 6–8 weeks). Wallerian degeneration does not occur, so recovery does not involve actual regeneration. There is frequently greater involvement of motor than sensory function with autonomic function being retained. In electrodiagnostic testing with nerve conduction studies, there is a normal compound motor action potential amplitude distal to the lesion at day 10, and this indicates a diagnosis of mild neurapraxia instead of axonotmesis or neurotmesis.
Sources: en.wikipedia.org
Enishi (Hokkaido) Teishu (Honshu) Iyo (Shikoku) Tsukushi (Kyushu) Ryugu (Okinawa) Like every other nation in the world, Yamato has its own Agents of the Four Seasons, each of whom has the duty to manifest their season in every part of the land. The Agents of Spring and Summer begin their journey on the island of Ryugu then move north, while the Agents of Autumn and Winter begin their journey on the island of Enishi, then head south. The role of "Agent" is bestowed by the deities of the seasons based on the physical, mental and spiritual eligibility of a blood descendant of the first Agent, and the chosen individual cannot in any way oppose their destiny. The bestowal occurs when the previous Agent dies or ceases to be eligible for the role. It is possible for an Agent, due to insufficient preparation or drastic events, to be unable to manifest their season, consequently extending the duration of the previous one. This is the case of the Agent of Spring, Hinagiku Kayo, a 16-year-old girl who was kidnapped by the Insurgents at the age of just 6. As a result, spring hasn't manifested in Yamato for 10 years, and winter, instead of lasting 3 months like the other seasons, has lasted 6 months during this period of time. However, the young Hinagiku has made her return and is now preparing to bring her season back to the nation, accompanied by her guard, Sakura Himedaka. It all begins on February 10th of the year 20 of the Reimei era, on the island of Ryugu.
The cytoskeleton is found underlying the cell membrane in the cytoplasm and provides a scaffolding for membrane proteins to anchor to, as well as forming organelles that extend from the cell. Indeed, cytoskeletal elements interact extensively and intimately with the cell membrane. Anchoring proteins restricts them to a particular cell surface—for example, the apical surface of epithelial cells that line the vertebrate gut—and limits how far they may diffuse within the bilayer. The cytoskeleton is able to form appendage-like organelles, such as cilia, which are microtubule-based extensions covered by the cell membrane, and filopodia, which are actin-based extensions. These extensions are ensheathed in membrane and project from the surface of the cell in order to sense the external environment and/or make contact with the substrate or other cells. The apical surfaces of epithelial cells are dense with actin-based finger-like projections known as microvilli, which increase cell surface area and thereby increase the absorption rate of nutrients. Localized decoupling of the cytoskeleton and cell membrane results in formation of a bleb.
=== Chemical === Meitnerium is the seventh member of the 6d series of transition metals, and should be much like the platinum group metals. Calculations on its ionization potentials and atomic and ionic radii are similar to that of its lighter homolog iridium; implying that meitnerium's basic properties will resemble those of the other group 9 elements: cobalt, rhodium, and iridium. Prediction of the chemical properties of meitnerium has not received much attention recently. Meitnerium is expected to be a noble metal. The standard electrode potential for the Mt3+/Mt couple is expected to be 0.8 V. Based on the most stable oxidation states of the lighter group 9 elements, the most stable oxidation states of meitnerium are predicted to be +6, +3, and +1, with the +3 state being the most stable in aqueous solutions. Rhodium and iridium show a maximum oxidation state of +6; the most stable states are +4 and +3 for iridium and +3 for rhodium. The oxidation state +9, represented only by iridium in IrO4+, might be possible for meitnerium nonafluoride MtF9 and the MtO4+ cation, though IrO4+ is expected to be more stable than these meitnerium compounds. The meitnerium tetrahalides have also been predicted to have similar stabilities to those of iridium, thus also allowing a stable +4 state. It is further expected that the maximum oxidation states of elements from bohrium (element 107) to darmstadtium (110) may be stable in the gas phase but not in aqueous solution.
== Pharmacokinetics == Trelagliptin's uniquely designed structure enhances its chemical stability and resistance to metabolic degradation. It binds strongly to the DPP-4 enzyme, with a slow dissociation rate (~30 minutes), compared to sitagliptin (3.5 min) and vildagliptin (<2 min). This prolonged binding contributes to its sustained DPP-4 inhibition. Trelagliptin has a long elimination half-life of approximately 54.3 hours. A 100 mg once-weekly dose maintained 77.4% DPP-4 inhibition 7 days post-dose. The drug reaches steady-state plasma levels (20.00–21.60 ng/mL) by week 4. These properties support its effective once-weekly dosing regimen.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.